Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau burden across Braak stages is associated with regionally specific amyloid accumulation.

Brain communications·2026
Same author

APOE ε4 and amyloid status moderate the associations between sleep, physical activity, and tau-PET burden in cognitively unimpaired older adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Diffusion Tensor Imaging Correlates of Financial Capacity Instrument-Short Form Completion Time in Mild Cognitive Impairment.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same author

Five-year change in brain metabolism across the spectrum of cognitive impairment in older adults: a quantitative MRI study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Unravelling cognitive frailty: perceptions, misconceptions, and the path to prevention.

The Gerontologist·2026
Same author

Diagnostic Accuracy of Point-of-Care Tests to Diagnose Vitamin D Deficiency in Adults and Children: Systematic Review.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Claire L Lancaster1, Nicholas Dowell1, Arnold Bakker2

  • 1Brighton & Sussex Medical School, Brighton, United Kingdom.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

Low-dose levetiracetam improved executive function in individuals without the APOE4 gene, but not in those with it. This suggests potential prophylactic use for non-APOE4 carriers at risk for Alzheimer's Disease.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Alzheimer's Disease (AD) progression may be slowed by low-dose levetiracetam.
  • This anti-seizure medication downregulates neuronal hyperactivity, a marker in early AD and in APOE4+ individuals.
  • The study investigates acute cognitive benefits of levetiracetam in healthy mid-age adults, examining effects by APOE4 genotype.

Purpose of the Study:

  • To determine if low-dose levetiracetam offers acute cognitive benefits in healthy middle-aged adults.
  • To assess whether the cognitive effects of levetiracetam differ between APOE33 and APOE4+ genotypes.
  • To explore the potential of levetiracetam as a prophylactic treatment for individuals at risk of AD.

Main Methods:

  • A double-blind, placebo-controlled study involving 58 adults (45-65 years old) with either APOE33 or APOE4+ genotype.
  • Participants received low-dose levetiracetam (125mg bidaily) or placebo for two weeks.
  • Cognitive performance was assessed using an executive switch-inhibition task, with data analyzed via generalized linear mixed effect modeling.

Main Results:

  • APOE4+ carriers exhibited poorer response inhibition accuracy and slower reaction times (RTs) irrespective of treatment.
  • Levetiracetam significantly improved accuracy and RT in APOE33 individuals, with greater speed benefits in younger participants.
  • No significant cognitive improvements were observed in APOE4+ carriers following levetiracetam treatment.

Conclusions:

  • Low-dose levetiracetam selectively enhanced executive function in APOE33 individuals, not APOE4+ carriers.
  • Findings support potential prophylactic use of levetiracetam in non-APOE4+ individuals at risk for AD.
  • Further research is needed to confirm levetiracetam's effects on brain hyperactivity and long-term outcomes in APOE4+ carriers.